Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / NKTX - Nkarta initiated as a buy at Raymond James on cancer therapy platform

NKTX - Nkarta initiated as a buy at Raymond James on cancer therapy platform

Nkarta Inc.
Raymond James has initiated Nkarta (NASDAQ:NKTX) with a buy rating citing the company's allogenic natural killer cell therapy platform for cancer. The firm has a $17 price target (~69% upside based on Thursday's close). Analyst Dane Leone said that he believes the natural killer platform has a wide range of possibilities to be used with other drug classes. He added that clinical data from a phase 1 trial of NKX101 expected in the first half of the year will provide proof of concept, and data from NKX019 in b-cell malignancies is expected before the end of the year. NKX101 is the company's lead candidate under investigation for acute myeloid leukemia and myelodysplastic syndromes. In October, Nkarta (NKTX) gained a license from MaxCyte (NASDAQ:MXCT) for the company's Flow Electroporation technology.

For further details see:

Nkarta initiated as a buy at Raymond James on cancer therapy platform
Stock Information
Company Name: Nkarta Inc.
Stock Symbol: NKTX
Market: NASDAQ
Website: nkartatx.com
Menu
NKTX NKTX Quote NKTX Short NKTX News NKTX Articles NKTX Message Board
Get NKTX Alerts

News, Short Squeeze, Breakout and More Instantly...